Skip to content

US · KPRX · BIOTECHNOLOGY

Kiora Pharmaceuticals, Inc. (KPRX) intrinsic value and stock valuation

$0.72as of 2026-11-21 · Mkt cap 11.26M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kiora Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values KPRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KPRX’s statements →

Kiora Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Encinitas, CA 92024 kiorapharma.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-10.84M
20122025
Free cash flow
-$-10.07M
20122025
Total equity
$16.1M+10.6% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$16M$0.00$0.00$0.00
Operating income-$-9.46M$4.51M-$-12.59M-$-12.31M-$-14.24M
Net income-$-10.84M$3.59M-$-12.51M-$-13.58M-$-13.77M
EPSd-$-2.64M$869.2K-$-23.17M-$-18.6M-$-57.38M
Operating cash flow-$-9.96M$8.56M-$-9.56M-$-10.43M-$-10.68M
Capital expenditure-$-110K-$-10K$0.00$0.00-$-60K
Free cash flow-$-10.07M$8.55M-$-9.56M-$-10.43M-$-10.74M
Total assets$24.3M$36.5M$13.7M$18.7M$20.1M
Total debt$370K$60K$110K$110K$210K
Net debt-$-8.33M-$-3.74M-$-2.35M-$-5.86M-$-7.65M
Total equity$16.1M$25.8M$6.11M$11.4M$14.6M
Cash and short-term investments$17.1M$26.8M$2.45M$5.96M$7.85M
Income statement
20252024202320222021
Revenue$0.00$16M$0.00$0.00$0.00
Cost of revenue$20K$0.00$0.00$0.00$0.00
Gross profit-$-20K$16M$0.00$0.00$0.00
Research and development expenses$10.8M$4.9M$4.03M$3.45M$5.35M
Selling, general and administrative expenses$5.75M$5.54M$4.66M$8.28M$5.32M
Other expenses-$-7.09M$1.05M$3.9M$580K$3.56M
Operating expenses$9.43M$11.5M$12.6M$12.3M$14.2M
Cost and expenses$9.46M$11.5M$12.6M$12.3M$14.2M
Interest income$890K$1.25M$170K$60K$0.00
Interest expense$20K$20K$10K$10K$10K
Depreciation and amortization$20K$20K$50K$40K$50K
Ebitda-$-12.07M$5.7M-$-12.36M-$-13.65M-$-13.91M
Operating income-$-9.46M$4.51M-$-12.59M-$-12.31M-$-14.24M
Total other income/expenses, net-$-2.66M$1.15M$160K-$-1.39M$270K
Income before tax-$-12.12M$5.66M-$-12.42M-$-13.7M-$-13.96M
Income tax expense-$-1.28M$2.07M$90K-$-110K-$-190K
Net income-$-10.84M$3.59M-$-12.51M-$-13.58M-$-13.77M
Weighted average shares outstanding$4.17M$3.87M$540K$730K$240K
Weighted average diluted shares outstanding$4.1M$4.13M$540K$730K$240K
Balance sheet
20252024202320222021
Cash and short-term investments$17.1M$26.8M$2.45M$5.96M$7.85M
Net receivables$3.32M$600K$2.05M$1.37M$530K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$21.8M$29.7M$4.74M$7.68M$8.99M
Property, plant and equipment, net$380K$60K$110K$170K$280K
Goodwill and intangible assets$2.06M$6.69M$8.81M$10.7M$10.8M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.5M$6.78M$8.97M$11M$11.1M
Total assets$24.3M$36.5M$13.7M$18.7M$20.1M
Accounts payable$1.06M$420K$210K$1.01M$160K
Short-term debt$160K$20K$50K$110K$120K
Deferred revenue$1.25M$0.00$0.00$0.00$0.00
Total current liabilities$3.63M$6.01M$1.63M$3.27M$1.61M
Long-term debt$200K$30K$60K$0.00$90K
Deferred revenue, non-current$1.25M$0.00$0.00$0.00$0.00
Total non-current liabilities$4.5M$4.72M$5.97M$4M$3.94M
Capital lease obligations$200K$60K$60K$110K$210K
Total liabilities$8.13M$10.7M$7.6M$7.27M$5.55M
Common stock$280K$270K$80K$20K$0.00
Retained earnings-$-154.22M-$-143.38M-$-146.98M-$-134.46M-$-120.88M
Accumulated other comprehensive income (loss)-$-250K-$-280K-$-180K-$-180K-$-90K
Total equity$16.1M$25.8M$6.11M$11.4M$14.6M
Total investments$8.39M$23M$0.00$0.00$0.00
Total debt$370K$60K$110K$110K$210K
Net debt-$-8.33M-$-3.74M-$-2.35M-$-5.86M-$-7.65M
Cash flow statement
20252024202320222021
Net income-$-10.84M$3.59M-$-12.51M-$-13.58M-$-13.77M
Depreciation and amortization$20K$20K$50K$40K$50K
Stock-based compensation$900K$660K$750K$460K$840K
Change in working capital-$-3.27M$3.67M-$-1.82M$670K-$-1.04M
Accounts receivable-$-2.41M$1.03M-$-550K-$-870K-$-440K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.12M$230K-$-810K$780K-$-310K
Net cash provided by operating activities-$-9.96M$8.56M-$-9.56M-$-10.43M-$-10.68M
Investments in property, plant and equipment-$-110K-$-10K$0.00$0.00-$-60K
Acquisitions, net$0.00$0.00$0.00$0.00-$-90K
Net cash used for investing activities$14.4M-$-22.66M$0.00$10K-$-160K
Common stock issued$270K$15M$6.97M$5.38M$17.8M
Common stock repurchased$0.00$0.00$0.00-$-20K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$270K$15.5M$5.97M$8.62M$17.6M
Net change in cash$4.9M$1.34M-$-3.55M-$-1.89M$6.67M
Cash at end of period$8.7M$3.8M$2.46M$6.01M$7.9M
Operating cash flow-$-9.96M$8.56M-$-9.56M-$-10.43M-$-10.68M
Capital expenditure-$-110K-$-10K$0.00$0.00-$-60K
Free cash flow-$-10.07M$8.55M-$-9.56M-$-10.43M-$-10.74M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kiora Pharmaceuticals, Inc.

        Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.

        CEO
        Brian Strem
        Employees
        13
        Beta
        -0.39

        Explore

        Frequently asked questions

        What is the intrinsic value of Kiora Pharmaceuticals, Inc. (KPRX)?

        InvestorsCraft does not currently publish an intrinsic value for KPRX. How the IC value is calculated.

        Is KPRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for KPRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.